CD79A and nasopharyngeal carcinoma: With the exception of BLLF3-IgA levels in early-stage NPC patients and controls (Fig. 4 and Supplemental Fig. S1), levels of all other seromarkers were significantly different (p < 0.05) between NPC patients (early-stage and advanced-stage) and controls in Cohort 1 (Fig. 4) and Cohort 2 (Supplemental Fig. S1).